Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDFulcrum Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.44 | -$0.44 | -$0.44 |
| Q2 2024 | 2 | -$0.41 | -$0.41 | -$0.41 |
| Q3 2024 | 2 | -$0.40 | -$0.40 | -$0.40 |
| Q4 2024 | 6 | -$0.34 | -$0.23 | -$0.28 |
| Q1 2025 | 4 | -$0.30 | -$0.22 | -$0.25 |
| Q2 2025 | 2 | -$0.25 | -$0.25 | -$0.25 |
| Q3 2025 | 2 | -$0.24 | -$0.24 | -$0.24 |
| Q4 2025 | 2 | -$0.24 | -$0.24 | -$0.24 |
Fulcrum Therapeutics, Inc. Earnings Date And Information
Fulcrum Therapeutics, Inc. last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-0.35 earnings per share for the quarter, topping analysts' consensus estimates of $-0.4 by $0.05. The company had revenue of 0 for the quarter and had revenue of 2.81 M for the year. Fulcrum Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.59 diluted earnings per share) and currently has a price-to-earnings ratio of -16.6. Fulcrum Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Fulcrum Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q2 2024 | -$0.40 | -$0.35 | 0.05 | $112,500 | $0 |
| 07/31/2024 | Q1 2024 | $0.01 | $0.89 | 0.88 | $14.82 M | $80.00 M |
| 05/13/2024 | Q4 2023 | -$0.44 | -$0.43 | 0.01 | $0 | |
| 02/27/2024 | Q3 2023 | -$0.44 | -$0.40 | 0.04 | $871,000 | |
| 11/07/2023 | Q2 2023 | -$0.44 | -$0.39 | 0.05 | $1.05 M | $759,000 |
| 08/03/2023 | Q1 2023 | -$0.44 | -$0.38 | 0.06 | $1.12 M | $880,000 |
| 05/15/2023 | Q4 2022 | -$0.47 | -$0.36 | 0.11 | $295,000 | |
| 06/23/2023 | Q3 2022 | -$0.45 | $685,000 | |||
| 11/08/2022 | Q2 2022 | -$0.62 | -$0.52 | 0.1 | $2.54 M | $1.18 M |
| 08/11/2022 | Q1 2022 | -$0.66 | -$0.83 | -0.17 | $2.96 M | $1.88 M |
| 05/09/2022 | Q4 2021 | -$0.63 | -$0.64 | -0.01 | $2.59 M | |
| 03/03/2022 | Q3 2021 | -$0.65 | -$0.58 | 0.07 | $5.06 M | |
| 11/04/2021 | Q2 2021 | -$0.64 | -$0.57 | 0.07 | $2.25 M | $4.94 M |
| 08/10/2021 | Q1 2021 | -$0.65 | -$0.60 | 0.05 | $2.40 M | $4.38 M |
| 05/06/2021 | Q4 2020 | -$0.66 | -$0.54 | 0.12 | $4.79 M | |
| 03/04/2021 | Q3 2020 | -$0.73 | -$0.64 | 0.09 | $4.23 M | |
| 11/10/2020 | Q2 2020 | -$0.66 | -$0.70 | -0.04 | $687,500 | $1.85 M |
| 08/11/2020 | Q1 2020 | -$0.80 | -$0.66 | 0.14 | $2.00 M | |
| 05/13/2020 | Q4 2019 | -$0.75 | -$0.81 | -0.06 | $750,000 | |
| 03/05/2020 | Q3 2019 | -$0.84 | -$0.71 | 0.13 | $0 |
Fulcrum Therapeutics, Inc. Earnings: FAQ's
When is Fulcrum Therapeutics, Inc.'s earnings date?
Fulcrum Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
Did Fulcrum Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Fulcrum Therapeutics, Inc. (:FULC) reported $-0.35 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.4 by $0.05.
How can I listen to Fulcrum Therapeutics, Inc.'s earnings conference
call?
The conference call for Fulcrum Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Fulcrum Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Fulcrum Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Fulcrum Therapeutics, Inc. generate each year?
Fulcrum Therapeutics, Inc. (:FULC) has a recorded annual revenue of $2.81 M.
How much profit does Fulcrum Therapeutics, Inc. generate each year?
Fulcrum Therapeutics, Inc. (:FULC) has a recorded net income of $2.81 M. Fulcrum Therapeutics, Inc. has generated $-1.59 earnings per share over the last four quarters.
What is Fulcrum Therapeutics, Inc.'s price-to-earnings ratio?
Fulcrum Therapeutics, Inc. (:FULC) has a price-to-earnings ratio of -16.6 and price/earnings-to-growth ratio is -1.37.